Pfizer paid $43 billion for Seagen in 2023. Not for the revenue. Not for the pipeline. For the ADC patent portfolio that locked in three approved drugs and 60-plus conjugation patents competitors could not replicate. Hayat Amin argues that the ADC competitive landscape is the clearest example in pharma of a single truth: the patent map — not the clinical data — determines who captures the next $30 billion in market value.
The antibody-drug conjugate space crossed $15 billion in global sales in 2025. Over 200 ADC candidates sit in clinical trials. And the IP ownership structure behind those candidates is more concentrated than most pharma executives realize. Beyond Elevation’s patent landscape analysis methodology applies the same framework to ADCs that it uses across every deep-tech vertical: map the claims, find the gaps, price the opportunity.
What Is the ADC Competitive Landscape in 2026?
The ADC competitive landscape is a $15 billion-plus market dominated by five pharma companies that collectively hold over 65% of granted ADC-related patent claims. Fourteen ADC drugs have received FDA or EMA approval, with another 200-plus candidates in clinical development. Six distinct linker-payload technology clusters account for the majority of filed patent families.
The concentration matters. When Pfizer closed the Seagen acquisition, it absorbed not just Adcetris, Padcev, and Tukysa but the conjugation platform patents that underpin next-generation ADC development. Daiichi Sankyo’s DXd (deruxtecan) payload technology — the engine behind Enhertu — sits behind a separate patent wall that AstraZeneca paid $6 billion to co-develop and co-commercialize.
These are not product-by-product battles. They are patent-portfolio wars. And the landscape is shifting fast.
Who Owns the Most ADC Patents?
Five companies control the majority of the ADC patent landscape. Pfizer-Seagen leads with the broadest conjugation-platform portfolio after the 2023 merger. Daiichi Sankyo holds the strongest single-payload patent estate through its DXd topoisomerase I inhibitor technology. Roche-Genentech retains foundational ADC patents from Kadcyla, the first-generation HER2-targeting ADC approved in 2013.
Beyond the top three, Gilead (through its Immunomedics acquisition) controls the Trop-2-directed payload-linker patents behind Trodelvy. AbbVie, through its 2020 Allergan merger and internal R&D, holds a growing estate in next-generation site-specific conjugation.
Hayat Amin’s Patent Mining Method applies directly here: most ADC patent holders undercount their licensable claims by 30–40% because they file around the drug molecule and miss the manufacturing process, the conjugation chemistry, and the analytical method patents that licensees actually need. Beyond Elevation’s landscape analysis for one biotech client uncovered 14 licensable patent families the client had classified as “defensive only.”
Which Linker Technologies Shape the ADC Competitive Landscape?
Six linker-payload technology clusters account for the majority of filed ADC patent families in 2026. The linker — the chemical bond connecting the antibody to its cytotoxic payload — is the most patented component of the ADC architecture because it controls drug release, therapeutic index, and manufacturing scalability.
1. Cleavable protease-sensitive linkers. The most widely patented category. Valine-citrulline (vc) and valine-alanine (va) dipeptide linkers cleave inside the tumor cell via cathepsin B. Seagen’s original vc-MMAE platform (Adcetris) sits behind the foundational patent estate that Pfizer now controls.
2. Non-cleavable thioether linkers. Roche’s Kadcyla uses a non-cleavable SMCC-DM1 linker that requires full antibody degradation for payload release. Fewer patent filings than cleavable linkers but strong freedom-to-operate barriers in the HER2 space.
3. DXd topoisomerase I payloads with tetrapeptide linkers. Daiichi Sankyo’s proprietary DXd payload coupled with a GGFG tetrapeptide linker. This is the technology behind Enhertu (trastuzumab deruxtecan), the ADC with the highest single-drug revenue projection through 2030. The patent estate is narrow but deep — difficult to license around.
4. Site-specific conjugation technologies. ThioBridge (Abzena), GlycoConnect (Synaffix), and Sutro’s cell-free expression system represent the next frontier. These technologies produce homogeneous ADCs with consistent drug-to-antibody ratios, addressing the manufacturing variability that plagued first-generation ADCs. Patent filings in this cluster grew 45% year-over-year from 2023 to 2025.
5. Bispecific ADC platforms. ADCs built on bispecific antibody backbones that target two antigens simultaneously. Zymeworks, AbbVie, and Merck hold the most relevant patent filings. Clinical data remains early-stage, but the patent race is already underway.
6. Immune-stimulating ADC (iADC) payloads. Instead of cytotoxic payloads, iADCs deliver STING agonists, TLR agonists, or other immune-activating molecules. Bolt Biotherapeutics and Mersana pioneered the early filings. The technology cluster is patent-sparse today — which makes it the clearest white-space opportunity in the ADC landscape.
What Targets Did Pfizer-Seagen Not Buy?
Pfizer’s $43 billion Seagen acquisition covered three approved drugs and a deep conjugation-platform estate. But two high-value target categories sit outside Pfizer-Seagen’s patent coverage — and both represent significant licensing or acquisition opportunities for ADC patent holders and developers entering the space.
Target 1: Trop-2-directed ADCs beyond Trodelvy. Gilead owns the Trop-2 ADC patent estate through Immunomedics. Pfizer holds no granted Trop-2-directed claims. As Trop-2 becomes a validated target across multiple solid tumor indications (breast, lung, urothelial), companies developing next-generation Trop-2 ADCs with differentiated payloads face a licensing decision between Gilead’s patent estate and freedom-to-operate strategies. Hayat Amin says this is exactly the scenario where a patent landscape analysis pays for itself ten times over — before you spend $20 million on Phase I, you need to know if your linker-payload combination triggers a Gilead claim.
Target 2: Claudin 18.2-directed ADCs. Claudin 18.2 is the gastric cancer target with the fastest-growing ADC patent activity in 2025–2026. Astellas (through its zolbetuximab antibody program), RemeGen, and several Chinese biotech firms hold early-stage patents. Neither Pfizer-Seagen nor Daiichi Sankyo have filed in this space. For founders building ADC platforms, Claudin 18.2 is one of the few target-antibody combinations where the patent landscape is not yet locked down by a top-five holder.
Hayat Amin’s IP Defensibility 7-Point Test applies to ADC portfolios with unusual clarity. An ADC portfolio scores high on defensibility when it covers the linker chemistry, the conjugation site, the payload mechanism, the manufacturing process, the analytical characterization method, the formulation, and at least one composition-of-matter claim on the final conjugate. Most ADC portfolios cover three of seven. The companies that cover six or more — Pfizer-Seagen, Daiichi Sankyo — command the premium multiples.
How Should ADC Patent Holders Structure Their IP Strategy?
ADC patent holders — whether pharma companies, biotech startups, or university spinouts — face three strategic decisions that determine whether their IP generates licensing revenue or sits dormant. The wrong call on any one of these three decisions leaves millions in potential licensing income on the table.
Decision 1: Platform vs. product patent strategy. Filing only around the drug molecule leaves the platform unprotected. The most valuable ADC patent estates protect the conjugation technology, not just the conjugate. Hayat Amin reminds founders that the platform patent is what licensees pay for — one product patent protects one drug, one platform patent protects a pipeline.
Decision 2: Offensive vs. defensive licensing posture. Some ADC patent holders file to block competitors. Others file to create licensing revenue streams. The difference is claim drafting. Claims written for litigation are narrow and specific. Claims written for licensing are broader, covering technology classes rather than individual molecules. The licensing approach typically generates 3–5x more revenue per patent family because it captures a wider set of potential licensees.
Decision 3: Geographic filing strategy. ADC manufacturing concentrates in the US, Switzerland, Japan, and increasingly China and South Korea. Filing patents only in the US leaves 40–60% of the licensable market uncovered. A structured international filing strategy — prioritizing countries where manufacturing, clinical development, and commercial sales converge — maximizes the geographic reach of the portfolio.
At Beyond Elevation, Hayat Amin’s team runs patent landscape analyses that map these decisions for ADC clients — who holds what, where the white space sits, and which filing strategy turns an existing portfolio from a cost center into a licensing engine. For a confidential assessment of your ADC patent position, schedule a consultation.
FAQ
How many ADC drugs are approved in 2026?
Fourteen antibody-drug conjugates have received FDA or EMA approval as of mid-2026, with Enhertu (trastuzumab deruxtecan) and Padcev (enfortumab vedotin) commanding the highest market share. Over 200 additional ADC candidates are in clinical trials across solid tumors and hematologic malignancies.
Who holds the most ADC patents?
Pfizer-Seagen holds the broadest ADC conjugation-platform patent portfolio following the $43 billion merger in 2023. Daiichi Sankyo holds the strongest single-payload estate through its DXd technology. Roche-Genentech, Gilead, and AbbVie round out the top five.
What is the fastest-growing ADC patent technology cluster?
Site-specific conjugation technologies grew 45% in patent filings year-over-year from 2023 to 2025. Immune-stimulating ADC (iADC) payloads represent the most patent-sparse cluster, making them the clearest white-space opportunity for new filers.
Can you license ADC linker technology?
Yes. ADC linker technology is among the most actively licensed IP in pharma. Royalty rates for ADC platform licenses typically range from 2–5% of net sales, with upfront payments ranging from $5 million to $50 million depending on exclusivity, field of use, and clinical-stage validation. See the patent licensing revenue model breakdown for full context.
What is white space in the ADC patent landscape?
White space refers to technology areas where no dominant patent holder has established claims. In the 2026 ADC competitive landscape, the clearest white spaces are immune-stimulating payloads (iADCs), Claudin 18.2-directed conjugates, and novel bispecific ADC architectures. Learn how white space analysis identifies these gaps systematically.